The novel tribody [(CD20)2xCD16] efficiently triggers effector cell-mediated lysis of malignant B cells

Rituximab infusion induces NK activation in lymphoma patients with the high-affinity CD16 polymorphism

(2011) S. Veeramani et al.   BLOOD

Novel type II anti-CD20 monoclonal antibody (GA101) evokes homotypic adhesion and actin-dependent, lysosome-mediated cell death in B-cell malignancies

(2011) W. Alduaij et al.   BLOOD

Fc gamma receptor IIb on target B cells promotes rituximab internalization and reduces clinical efficacy

(2011) S. H. Lim et al.   BLOOD

Interindividual Variability of Response to Rituximab: From Biological Origins to Individualized Therapies

(2011) G. Cartron et al.   CLINICAL CANCER RESEARCH

Monoclonal antibodies in the treatment of hematologic malignancy

(2010) Edward D. Ball et al.   BEST PRACTICE & RESEARCH CLINICAL HAEMATOLOGY

Increasing the efficacy of CD20 antibody therapy through the engineering of a new type II anti-CD20 antibody with enhanced direct and immune effector cell-mediated B-cell cytotoxicity

(2010) E. Mossner et al.   BLOOD

In vivo Cytotoxicity of Type I CD20 Antibodies Critically Depends on Fc Receptor ITAM Signaling

(2010) S. de Haij et al.   CANCER RESEARCH

Effector Cell Recruitment with Novel Fv-based Dual-affinity Re-targeting Protein Leads to Potent Tumor Cytolysis and in Vivo B-cell Depletion

(2010) Syd Johnson et al.   JOURNAL OF MOLECULAR BIOLOGY

Bispecific antibodies for cancer therapy

(2010) Patrick Chames et al.   mAbs

Rituximab: Mechanism of Action

(2010) George J. Weiner   SEMINARS IN HEMATOLOGY

Depletion of the C3 component of complement enhances the ability of rituximab-coated target cells to activate human NK cells and improves the efficacy of monoclonal antibody therapy in an in vivo model

(2009) S.-Y. Wang et al.   BLOOD

Anti-CD20 monoclonal antibodies: historical and future perspectives

(2009) S. H. Lim et al.   HAEMATOLOGICA

Antibody fucosylation differentially impacts cytotoxicity mediated by NK and PMN effector cells

(2008) M. Peipp et al.   BLOOD

Fc RIIIa Expression Is Not Increased on Natural Killer Cells Expressing the Fc RIIIa-158V Allotype

(2008) N. Congy-Jolivet et al.   CANCER RESEARCH

Hirudin versus heparin for use in whole bloodin vitrobiocompatibility models

(2008) Fredrik Bexborn et al.   JOURNAL OF BIOMEDICAL MATERIALS RESEARCH PART A

Immunoglobulin G Fragment C Receptor Polymorphisms and Clinical Efficacy of Trastuzumab-Based Therapy in Patients With HER-2/neu–Positive Metastatic Breast Cancer

(2008) Antonino Musolino et al.   JOURNAL OF CLINICAL ONCOLOGY

A Novel CD19-directed Recombinant Bispecific Antibody Derivative With Enhanced Immune Effector Functions for Human Leukemic Cells

(2008) Christian Kellner et al.   JOURNAL OF IMMUNOTHERAPY

Tumor Regression in Cancer Patients by Very Low Doses of a T Cell-Engaging Antibody

(2008) R. Bargou et al.   SCIENCE